© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Shared insight on the role cardiovascular disease management plays in the prostate cancer treatment paradigm.
December 20th 2021
Expert perspectives on prostate cancer with deference to clinical presentations, diagnosis, and prognosis.
March 2nd 2022
A broad look at the economic burden of prostate cancer and outlook in regard to survival within the current treatment landscape.
Shared insight on the correlation between prostate cancer and cardiovascular disease, with a focus on the attributes that increase a patient’s risk.
March 9th 2022
A comprehensive review of the therapeutic classes available for patients with prostate cancer.
Focusing on available agents in prostate cancer, experts consider how androgen deprivation therapy impacts risk of cardiovascular disease.
March 16th 2022
A brief review of factors that may put patients with prostate cancer at increased risk for developing cardiovascular disease.
Experts consider available professional society guidelines on prostate cancer and cardiovascular disease management.
March 23rd 2022
Shared insight on the impact that cardiovascular disease has on cost of care in prostate cancer.
Continuing their discussion on cost of care in prostate cancer, experts reflect on how cardiovascular disease impacts risk-bearing practices and alternative payment models.
March 30th 2022
Expert perspectives on factors that inform prostate cancer therapy selection while keeping cardiovascular disease in mind.